本港累計接種逾540萬劑新冠疫苗
政府公佈,疫苗接種計劃展開至今,已爲參與計劃人士接種約540.16萬劑疫苗。其中,約309.97萬人已接種首劑疫苗,約230.19萬人已接種第二劑疫苗。
已接種首劑疫苗人士中,約122.82萬人接種科興疫苗,約187.15萬人接種復必泰疫苗;第二劑科興及復必泰接種人數分別爲約93.72萬人及約136.46萬人。
截至昨日(27日)晚上八時的過去24小時,約有6.48萬人經計劃接種疫苗。社區疫苗接種中心接種科興疫苗和復必泰疫苗的整體接種率均爲約96%。昨日約4,000人在網上預約接種第一劑和第二劑科興疫苗,約1.87萬人預約接種第一劑和第二劑復必泰疫苗。
另外,截至昨日凌晨,過去24小時有12宗送院個案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.